ViaDerma, Inc.
VDRM · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -30.47 | -0.06 | -0.13 | 0.14 |
| FCF Yield | 0.00% | -0.02% | 0.02% | -0.58% |
| EV / EBITDA | 158.53 | 9.42 | -10.31 | -7.40 |
| Quality | ||||
| ROIC | 41.53% | -17.15% | -16.24% | 4.42% |
| Gross Margin | 99.97% | 99.96% | 99.48% | 94.45% |
| Cash Conversion Ratio | 0.04 | 0.02 | -0.01 | 0.02 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.32% | 261.25% | 267.04% | -37.05% |
| Free Cash Flow Growth | 111.73% | -204.70% | 116.25% | 41.99% |
| Safety | ||||
| Net Debt / EBITDA | 3.87 | 0.59 | -0.46 | -2.05 |
| Interest Coverage | 2.42 | 2.48 | 2.95 | -0.47 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.01 |
| Cash Conversion Cycle | -32,004.40 | -21,315.07 | -4,426.27 | 28,767.33 |